Healthcare is a little strange insofar as companies and analysts often correctly identify promising markets, but real commercial acceptance and usage takes quite a bit longer than most expect. In the case of AtriCure (ATRC), investors have long pondered the multi-billion dollar potential of an effective atrial fibrillation therapy, but the company had a long road to FDA approval and still has to sell and train a sometimes surprisingly stubborn medical community.
While the road ahead for AtriCure is still long (and uphill), the market potential here is such that successful marketing efforts could make this a very interesting stock in the coming years.
Click here for more:
AtriCure Could Start Paying Off
No comments:
Post a Comment